Kobayashi factory searched over deaths possibly linked to supplements

Published Sat, Mar 30, 2024 · 11:59 AM

JAPANESE health officials searched a Kobayashi Pharmaceutical factory on Saturday (Mar 30) after the drugmaker reported five deaths possibly linked to dietary supplements using red yeast rice, an official said.

The Ministry of Health, Labour and Welfare and the City of Osaka jointly inspected the factory in Osaka that had made the supplements containing “Beni-Koji” red yeast, suspected of having caused health damage, the ministry official said.

News footage showed officials entering the factory, and the official said the ministry could search other related locations.

The Osaka-based company could not immediately be reached for comment.

Kobayashi said on Friday it was investigating a suspected link between the products and their effects on the kidney since it received reports of kidney disease linked to the products.

As of Thursday evening, 114 people had been hospitalised and five had died after taking the supplements, which were marketed as helping lower cholesterol levels, according to the company.

A NEWSLETTER FOR YOU
Friday, 2 pm
Lifestyle

Our picks of the latest dining, travel and leisure options to treat yourself.

Kobayashi said it is examining the earnings impact of the latest issues.

The company has been recalling products with Beni-Koji in recent days after receiving reports of kidney ailments.

A Chinese consumers association urged consumers to stop using affected products, saying it was concerned about the risk of Kobayashi products, state media reported on Friday.

Beni-Koji contains Monascus purpureus, a red mould that is also used as a red colouring in some foods. REUTERS

KEYWORDS IN THIS ARTICLE

READ MORE

BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to  t.me/BizTimes

International

SUPPORT SOUTH-EAST ASIA'S LEADING FINANCIAL DAILY

Get the latest coverage and full access to all BT premium content.

SUBSCRIBE NOW

Browse corporate subscription here